Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
Savara, Inc. (SVRA)
Last savara, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
savarapharma.com/investors/events-presentations
Company Research
Source: Business Wire
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European Patent Office (EPO) has issued patent No. 4 496 611 titled, “Drug-Device Combination Comprising a Liquid Solution and a Nebulizer for Aerosolization of the Liquid Solution.” The patent is jointly held by Savara and PARI and covers the combination of Savara’s investigational therapy, MOLBREEVI, and PARI’s investigational eFlow® Nebulizer System that has been optimized for the delivery of MOLBREEVI.“This patent covers our drug-device combination through March 2043,” said Matt Pauls, J.D., M.B.A, Chair and Chief Executive Officer, Savara. “With 10 years of Orphan Drug regulatory exclusivity upon EU approval, as well as our exclusive license with PARI, this patent strengthens the long-term protection of MOLBREEVI for the treatment of autoimmune PAP in Europe. As we prepare for a December resubmission of the M
Show less
Read more
Impact Snapshot
Event Time:
SVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SVRA alerts
High impacting Savara, Inc. news events
Weekly update
A roundup of the hottest topics
SVRA
News
- Savara Inc. ticks higher amid takeover speculation [Seeking Alpha]Seeking Alpha
- Savara Announces Participation in Upcoming Investor Healthcare ConferencesBusiness Wire
- Savara: A High-Risk Opportunity [Seeking Alpha]Seeking Alpha
- Savara (NASDAQ:SVRA) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $8.00 to $9.00. They now have an "outperform" rating on the stock.MarketBeat
- Savara (NASDAQ:SVRA) had its price target lowered by analysts at Citizens Jmp from $11.00 to $10.00. They now have a "market outperform" rating on the stock.MarketBeat
SVRA
Earnings
- 11/12/25 - Miss
SVRA
Sec Filings
- 12/4/25 - Form 4
- 12/4/25 - Form 4
- 11/17/25 - Form 4
- SVRA's page on the SEC website